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ABSTRACT
Febrile neutropenia is still associated with a high mortality rate, making timely and efﬁcient empirical
antibiotic therapy absolutely vital. For these reasons, evidence-based guidelines are urgently needed.
The guidelines published so far are mainly based on clinical experience and selective citation. This
review summarises studies and meta-analyses concerning empirical antibiotic therapy in high-risk
neutropenic patients: (1) No beneﬁt results from the addition of an aminoglycoside to the initial
empirical therapy. On the contrary, patients who received an aminoglycoside had a signiﬁcantly higher
rate of adverse events, especially nephrotoxicity. (2) The empirical addition of a glycopeptide after
3–4 days of persistent fever was evaluated in two randomised controlled trials. Combined analysis
demonstrates that in clinically stable patients without resistant or skin ⁄ soft tissue infections, the use of a
glycopeptide can be delayed for another 3–4 days. (3) The choice of drugs for monotherapy is currently
being evaluated; preliminary results demonstrate that ceftazidime has a signiﬁcantly inferior response
rate (without modiﬁcation) to other evaluated antibiotics. In conclusion, guidelines should be based on
the systematic evaluation of all relevant clinical trials. The analysis of the existing data leads to the
recommendation of monotherapy, without aminoglycoside, using piperacillin–tazobactam, cefepime,
meropenem or imipenem–cilastin, any of which may be continued for up to 7 days in persistently
febrile, clinically stable patients without skin ⁄ soft tissue infections. The choice of drug as standard ﬁrst-
line therapy should depend on drug costs, local resistance rates and the potential for resistance
induction.
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INTRODUCTION
More than 80% of patients who have undergone
myelosuppressive chemotherapy for acute leuk-
aemia have at least one episode of fever during
the period of neutropenia. Despite the empirical
use of broad-spectrum antibiotic agents, a fatality
rate of 5–10% is seen in most trials. Timely and
effective empirical antibiotic therapy is an abso-
lute necessity and has greatly improved the
outcome for these patients [1,2].
A series of European Organisation for Research
and Treatment of Cancer (EORTC) studies from
1973 to 1993 demonstrated a shift from Gram-
negative to Gram-positive organisms in microbi-
ologically documented infections in these patients
[3]. The predominant organisms involved are
Staphylococcus aureus, coagulase-negative staphy-
lococci, streptococci (viridans, group A, Strepto-
coccus pneumoniae), Eschericha coli, Klebsiella
pneumoniae, Pseudomonas aeruginosa and Haemo-
philus inﬂuenzae.
This shift was presumed to be due to the
introduction of effective prophylaxis with quino-
lone antibiotics against Gram-negative organisms
but the most recent EORTC review of reported
episodes of proven single-organism bacteraemias
shows that there has been a resurgence of Gram-
negative infections. Between 1993 and 2000, the
incidence rates of Gram-negative and Gram-posit-
ive infections have been roughly the same (12%
and 13%, respectively), with a signiﬁcant increase
in the rate of Gram-negative infections (6.5% vs.
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12%, p < 0.01) [4]. This recent re-emergence of
Gram-negative infections has happened despite
the continuing use of quinolone prophylaxis and
has been reported by units still using such Gram-
negative prophylaxis [5], those which have
recently abandoned this approach [6] and those
which have never used it [7]. The ﬂuctuating rates
of Gram-positive and Gram-negative infections
emphasise the need for broad-spectrum antibiotics
in the empirical ﬁrst-line therapy of febrile neu-
tropenia.
Non-bacterial infections are mostly caused by
fungi (Candida spp. and Aspergillus spp.), whereas
patients may encounter severe viral (herpes sim-
plex, varicella-zoster, Epstein–Barr virus and cy-
tomegalovirus) and protozoal (Toxoplasma gondii)
infections after allogeneic stem-cell transplanta-
tion [8,9]. However, an identiﬁcation of the
causative agents will be possible only in approxi-
mately one-third of patients, so the majority of
patients need empirical antibiotic therapy for
fever of unknown origin.
CLINICAL PRACTICE GUIDELINES
Recommendations to guide clinical practice in
the treatment of these infections have been
published in some countries. Whereas two
guidelines are available from the USA,
only two European guidelines could be found
despite an intensive search (via MedLine, Google,
and contact with experts in various countries)
[9–12].
These guidelines differentiate between low-risk
patients, who are likely to receive oral antibiotics,
and patients at higher risk, who should be treated
in hospital with intravenous antibiotics. This
review will consider further the intermediate- or
high-risk patients only (usually those with a
duration of neutropenia of more than 5 days), as
there is a broad consensus on the treatment of
low-risk patients.
By deﬁnition, where a causative organism is
unknown or not suspected on clinical grounds,
empirical broad-spectrum antibiotic therapy is
recommended. For intermediate- or high-risk
neutropenic patients with fever of unknown
origin, current guidelines recommend either
broad-spectrum monotherapy or combination
therapy where an aminoglycoside is added.
Table 1 lists the recommended antibiotics from
the four published guidelines. In certain risk
situations, speciﬁc antibiotics are needed (e.g.,
glycopeptides in the case of central venous line or
skin ⁄deep tissue infections) in addition to the
empirically chosen antibacterials.
Table 1. Recommendations from clinical practice guidelines for empirical initial antibiotic therapy in neutropenic patients
with fever of unknown origin and no particular risk factors
Guideline Monotherapy Combination therapy
IDSA (Infectious Disease
Society of America) [9]
Ceftazidime Aminoglycoside + piperacillin–tazobactam ⁄
ticarcillin ⁄ clavulanate
Cefepime Aminoglycoside + cefepime–ceftazidime
Imipenem–cilastatin Aminoglycoside + imipenem–cilastatin
Meropenem Aminoglycoside + meropenem
Piperacillin–tazobactama
NCCN (National Comprehensive
Cancer Network) [10]
Ceftazidime Aminoglycoside + anti-pseudomonal penicillinb
Cefepime Aminoglycoside + extended-spectrum cephalosporin
Imipenem–cilastatin Ciproﬂoxacin + anti-pseudomonal penicillin
Meropenem Double b-lactam
IHO (Infectious Diseases Working
Party of the German Society of
Hematology and Oncology) [11]
Piperacillin–tazobactam Aminoglycoside + acylaminopenicillin
Ceftazidime
Cefepime Aminoglycoside + third- or fourth-generation
cephalosporinc
Imipenem–cilastatin
Meropenem
SEQ (Chemotherapy Society
of Spain) [12]
Cefepime Not recommended for routine use
Meropenem
Piperacillin–tazobactam
aPiperacillin–tazobactam has been found to be effective monotherapy.
bWith or without b-lactamase inhibitor.
cCeftazidime, cefepime, ceftriaxone.
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None of these guidelines, however, is evidence-
based in the sense that a complete review of the
relevant literature was undertaken to formulate
the recommendations. Guidance is therefore
based mainly on expert opinions and current
practice as well as on a selection of clinical trials.
Such a review, however, would be a considerable
task. Even a very simple PubMed search (key
words: [fever OR infection] and neutropen*; limit:
randomized controlled trial) revealed 716 cita-
tions.
This article will review existing meta-analyses
related to this subject and compare these results
with the recommendations in the guidelines. As
the principles of evidence-based medicine and
meta-analysis have not often been applied to
infectious diseases, a short introduction to these
principles will be given ﬁrst.
EVIDENCE-BASED MEDICINE AND
META-ANALYSIS
David Sackett, one of the pioneers of evidence-
based medicine, has deﬁned it as ‘the integration
of best research evidence with clinical expertise
and patient values’ [13]. Best research evidence
usually refers to randomised controlled trials, but
when these are not available, other evidence must
be used.
Systematic reviews attempt to minimise bias
and random errors by a complete review of
published and unpublished data, assessment of
possible bias and, as and where appropriate, a
quantitative synthesis of independent random-
ised controlled trials (meta-analysis) [14].
An important example of the advantages of
such a quantitative synthesis is reported by
Egger et al. [14,15]. Lau et al. have published a
cumulative meta-analysis of the trials of intra-
venous streptokinase in acute myocardial infarc-
tion and demonstrated that a statistically
signiﬁcant combined difference in total mortality
of approximately 20% was achieved by 1973
[14,16]. After that date, a further 17 000 patients
were enrolled in the placebo arms of subsequent
trials (including two that were very large) until
the drug was eventually licensed in most coun-
tries. Some of the deaths in the placebo arms
could have been prevented if the efﬁcacy of the
treatment had been recognised earlier. Meta-
analysis became routinely available only at the
end of the 1970s.
Antman et al. correlated in 1992 the evidence
of cumulative meta-analysis with the recommen-
dations made by experts in review articles and
textbooks [14,17]. They found a 14-year delay
before the inclusion of an important therapeutic
advance (thrombolytic therapy) in textbooks and
review articles and the failure to realise and
describe the harmful effects of another interven-
tion (prophylactic use of lidocaine). These alarm-
ing ﬁndings, however, have not led to a general
acceptance of systematic reviews or meta-analy-
sis.
A systematic review should be a carefully
planned research project with a clearly formulat-
ed question, a priori deﬁnitions of eligibility
criteria for trials to be included, and the relevant
outcomes that will be extracted in a written
protocol. A comprehensive search for relevant
trials (published or unpublished) and an assess-
ment of their methodological quality is necessary.
The results of all trials should be displayed
graphically, either as the odds ratio (the odds
being the ratio of the number of patients with an
event to the number of patients without this
event) or the relative risk ratio (number of
patients with event ⁄ total number of patients) of
both treatment arms. This graph allows visual
examination of the degree of heterogeneity
between trials. If possible, a quantitative synthesis
should be done which will allow the estimation of
the overall effect. Finally, a sensitivity analysis
should test the robustness of the combined esti-
mates with respect to the effect of different
methodological and clinical variables [18].
THE USE OF AMINOGLYCOSIDES IN
EMPIRICAL ANTIBIOTIC THERAPY
IN FEBRILE NEUTROPENIC
PATIENTS
As shown above, most guidelines for the treat-
ment of fever in neutropenic patients recommend
the use of a combination therapy of b-lactam
antibiotics with aminoglycosides as a therapeutic
alternative to monotherapy with a b-lactam anti-
biotic alone (Table 1). Many randomised trials
have now compared these alternative therapeutic
approaches, but there is no consensus on the
superiority of one regimen over the other.
Two meta-analyses have explored the use of
aminoglycosides for this indication [19–21].
Furno et al. analysed 29 trials and 4795 febrile,
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neutropenic patients and found no statistically
detectable heterogeneity between these trials,
although their design and the interventions dif-
fered. Overall, the rate of treatment failure was in
favour of monotherapy (Peto odds ratio 0.88, 95%
conﬁdence interval (CI) 0.78–0.99). A cumulative
meta-analysis within this study demonstrated that
these effects have remained stable since 1996. Paul
et al. performed a Cochrane review and included
more trials (47 trials, 7807 patients). The main
results were not different from those of Furno et al.
(Table 2), and an analysis of adverse events
demonstrated an important difference for the
development of renal failure (relative risk 0.49,
95% CI 0.36–0.65; p < 0.05). The rate of disconti-
nuation of a study drug was also higher in the
combination therapy arms. In the Paul et al. study,
subgroup analysis differentiated between studies
that used the same b-lactam antibiotic in both arms
and those using different b-lactams (Table 2).
However, monotherapy was at least equivalent to
combination therapy in all comparisons. This was
independent of the number of daily doses of the
aminoglycoside.
In conclusion, there is no therapeutic advantage
to using aminoglycosides in the empirical antibi-
otic therapy of febrile neutropenic patients, but
there is clearly a higher rate of adverse events,
mainly nephrotoxicity. Long-term ototoxicity is
also possible, even with good monitoring of levels.
This recommendation does not apply to the treat-
ment of microbiologically documented infections,
where combination therapy is generally recom-
mended, e.g., against Pseudomonas aeruginosa.
THE USE OF GLYCOPEPTIDES IN
EMPIRICAL ANTIBIOTIC THERAPY
OF NEUTROPENIC FEVER
It is still standard practice in many centres to
modify empirical antibiotic therapy and to add a
glycopeptide after a period of persistent fever as
short as 48–96 h. This is due to the supposition,
perhaps mistaken in view of the recent EORTC
data [4], of a predominance of Gram-positive
infections, making the use of glycopeptides very
attractive. On the other hand, the rising rate of
glycopeptide-resistant Gram-positive bacteria
makes restriction of the use of these substances
necessary [22].
Two randomised clinical trials have evaluated
use of an additional glycopeptide vs. placebo in
persistently febrile but clinically stable patients
with no evidence of resistant or predominantly
Gram-positive infections (Table 3) [23–25]. In both
trials (one included 114 patients and used tei-
coplanin, and the other included 165 patients and
used vancomycin), the addition of the glycopep-
tide after 48–96 h did not improve the response
rate or the survival rate compared to placebo. In a
commentary on the articles in Cancer Treatment
Reviews, a quantitative synthesis of the two trials
was done and no difference for overall survival
(Peto odds ratio 0.80; 95% CI 0.33–1.90) or
response without modiﬁcation (Peto odds ratio
1.05; 95% CI 0.66–1.67) could be found [25].
Although the combined trials included only 279
patients, this meta-analysis shows clearly that
there is no evidence to support the early use of a
glycopeptide in clinically stable patients without
evidence of either a resistant organism or a
skin ⁄ soft tissue infection.
WHICH B -LACTAM ANTIBIOTIC FOR
MONOTHERAPY IN FEBRILE
NEUTROPENIC PATIENTS?
Table 1 lists the current recommendations in
clinical practice guidelines for antibiotic mono-
therapy. Ceftazidime, cefepime, meropenem,
imipenem–cilastatin and piperacillin–tazobactam
are listed. The US guidelines do not list pipera-
Table 2. Meta-analysis of b-lactam monotherapy vs. b-lactam–aminoglycoside combination therapy for fever with
neutropenia [21]
Monotherapy vs.
combination therapy All-cause fatality
Treatment failure
(same b-lactam)
Treatment failure
(different b-lactams)
All studies 0.85 (0.72–1.02) (n ¼ 30)a 1.12 (0.96–1.29) (n ¼ 9) 0.87 (0.80–0.93) (n ¼ 38)
Patients with haematological
malignancy
0.78 (0.58–1.06) (n ¼ 13) 0.92 (0.76–1.12) (n ¼ 4) 0.83 (0.73–0.96) (n ¼ 13)
Patients with severe neutropenia 0.66 (0.35–1.26) (n ¼ 5) 1.49 (1.13–1.97) (n ¼ 2) 0.94 (0.75–1.18) (n ¼ 6)
aRelative risk with 95% conﬁdence interval and number of studies reporting the relevant outcome. A relative risk below 1
favours monotherapy.
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cillin–tazobactam, because of a lack of clinical
experience in the U.S.A. at the time of their
publication, and the Spanish guidelines do not list
ceftazidime. None of the guidelines used a syste-
matic review of published evidence on which to
base its recommendations of published evidence.
There is no recent meta-analysis addressing
this question. A preliminary analysis of 25 rand-
omised clinical trials with 7274 patients is pre-
sented here. In this preliminary analysis, only
those trials that were available in electronic
databases (randomised clinical trials of one of
the above-mentioned antibiotics in each arm, with
or without additional aminoglycosides in neu-
tropenic patients) and published up to August
2002 were included. The extracted outcome was a
response to the initial empirical antibiotic treat-
ment without modiﬁcation. Table 4 lists the
results of this analysis, which demonstrate the
clear and statistically signiﬁcant inferiority of
ceftazidime and point to the equivalence of
piperacillin–tazobactam, cefepime, meropenem
and imipenem–cilastatin.
We have to emphasise again that this analysis is
preliminary and will be continued. However, we
think that the inferiority of ceftazidime (with or
without additional aminoglycoside) is not an
unexpected ﬁnding in view of its restricted
activity against Gram-positive bacteria [26].
IMPLICATIONS FOR CLINICAL
PRACTICE
In view of the above-mentioned data, an evi-
denced-based recommendation for initial empir-
ical monotherapy with piperacillin–tazobactam,
cefepime, meropenem or imipenem–cilastatin in
neutropenic patients with fever of unknown
origin can be made. The addition of a glycopep-
tide can be delayed for 6 or 7 days of persistent
fever in clinically stable patients without evidence
of skin ⁄ soft tissue infections and with no micro-
biological evidence to the contrary. The choice of
initial antibiotic may depend on the local hospital
resistance rates, the risk of inducing resistant
bacteria (which has been frequently reported for
Table 3. Proﬁle of two randomised trials evaluating the empirical use of glycopeptides in persistently febrile neutropenic
patients [23,24]
Erjavec et al. [23] Cometta et al. [24]
Initial empirical antibiotic Imipenem–cilastatin Piperacillin–tazobactam
Additional glycopeptide Teicoplanin Vancomycin
Inclusion criteria Persistent fever after 72–96 h
of initial empirical antibiotic therapy
Persistent fever after 48–62 h of initial
empirical antibiotic therapy
Exclusion criteria Resistant infections, central venous
catheter infections, suspected fungal infections,
clinical deterioration
Resistant infections, central venous
catheter infections, proven fungal or
viral infections, pulmonary inﬁltrates,
clinical deterioration
Response without treatment
modiﬁcation
45% vs. 47%a 49% vs. 46%
Overall survival 89% vs. 93% 95% vs. 90%
aGlycopeptide vs. placebo; all results were not signiﬁcantly different.
Table 4. Preliminary data of a
meta-analysis of b-lactam antibiotic
for empirical monotherapy in febrile
neutropenic patients
Patients
(trials)
Odds
ratioa p
Carbapenemb vs. ceftazidime 3306 (12) 0.75 0.001
Carbapenem vs. cefepime 697 (2) 1.22 0.223
Piperacillin–tazobactam vs. other cephalosporinsc 391 (2) 0.67 0.049
Piperacillin–tazobactam vs. ceftazidime 1237 (4) 0.67 0.001
Piperacillin–tazobactam vs. cefepime 453 (2) 1.00 0.983
Carbapenem vs. piperacillin–tazobactam 552 (2) 1.22 0.223
aAn odds ratio below 1 favours the antibiotic named ﬁrst.
bMeropenem or imipenem–cilastatin.
cCeftriaxone or cefpirome.
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cephalosporins and carbapenems [26]) and drug
acquisition costs. This has led to the choice of
piperacillin–tazobactam in EORTC trials and in
our institutions, where we can use a broad-
spectrum agent while decreasing the overall
usage of cephalosporins.
It is difﬁcult for practising clinicians to ﬁnd and
read all relevant clinical randomised trials on a
particular subject, but systematic reviews should
receive special attention and will be helpful in
guiding clinical practice decisions.
IMPLICATIONS FOR RESEARCH AND
GUIDELINE DEVELOPMENT
Obviously, more systematic reviews on the treat-
ment of infectious complications in neutropenic
patients are needed. These should receive ade-
quate and independent funding. Guideline pre-
paration should include a systematic review to
avoid incomplete, misleading or contradictory
recommendations.
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